Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Famotidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 7/20 | 0.62 |
| ▸ | CA1 | P00915 | 7/20 | 0.62 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | CA4 | P22748 | 7/20 | 0.62 |
| ▸ | CA9 | Q16790 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.62 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.62 |
| ▸ | CA6 | P23280 | 2/20 | 0.62 |
| ▸ | CA5A | P35218 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.62 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.62 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.62 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Famotidine SCHEMBL458654 | 0.79 | HRH2 (1.00) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL22127098 | 0.78 | HRH2 (0.98) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL18335717 | 0.77 | HRH2 (0.88) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL9817308 | 0.77 | HRH2 (0.95) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL1863206 | 0.77 | HRH2 (0.95) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL2321295 | 0.75 | HRH2 (0.88) | CA12CA1CA2CA4CA9 | |
| SCHEMBL23804924 | 0.73 | HRH2 (0.87) | CA12CA1CA2CA4CA9 | |
| SCHEMBL23804922 | 0.73 | HRH2 (0.87) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL1230949 | 0.73 | HRH2 (0.75) | CA12CA1CA2CA4CA9 | |
| Famotidine SCHEMBL9465678 | 0.73 | HRH2 (0.75) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707181-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170095422-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS | POZEN INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9364439-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9345695-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160089337-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS | POZEN INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160074376-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS | POZEN INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9198888-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150297543-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS | POZEN INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9161920-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150125524-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS | POZEN INC. (US) | 2015-05-07 | — | — | US | disclosed |
| EP-1411900-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | POZEN INC (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100172983-A1 | Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole | POZEN INC. | 2010-07-08 | — | — | US | disclosed |
| EP-2163241-A1 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | Pozen, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2010009432-A1 | NSAID DOSE UNIT FORMULATIONS WITH H2-RECEPTOR ANTAGONISTS AND METHODS OF USE | HORIZON THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-1411900-A4 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | POZEN INC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20050249811-A1 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2005-11-10 | — | — | US | disclosed |
| US-6926907-B2 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. (US) | 2005-08-09 | — | — | US | disclosed |
| EP-1411900-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | Pozen, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030069255-A1 | Pharmaceutical compositions for the coordinated delivery of NSAIDs | POZEN INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002098352-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs | POZEN INC. (US) | 2002-12-12 | — | — | WO | disclosed |